If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
42.40    0.00 (0.00%)
Bid:
41.40
Ask:
43.40
Spread: 2.00 (4.831%)
Market Cap: £65.92m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Statement re NAV and Final Dividend

4 Feb 2022 09:45

RNS Number : 7485A
Maven Income and Growth VCT 3 PLC
04 February 2022
 

Maven Income and Growth VCT 3 PLC

 

Net Asset Value and Proposed Final Dividend

 

The Directors of Maven Income and Growth VCT 3 PLC ("the Company") confirm that the unaudited net asset value of the Company as at 30 November 2021 was 62.55p per Ordinary Share.

 

The Directors propose that a final dividend of 1.50p per Ordinary Share, in respect of the year ended 30 November 2021, be paid on 26 April 2022 to Shareholders on the register at close of business on 25 March 2022.

The Company has in place a Dividend Investment Scheme (DIS) through which Shareholders may elect to have their dividend payments used to apply for new Ordinary Shares issued by the Company under the standing authority requested from Shareholders at Annual General Meetings. Shares issued under the DIS should qualify for VCT tax reliefs applicable for the tax year in which they are allotted. Terms & conditions of the scheme, together with a mandate form, are available from the Company's website at: www.mavencp.com/migvct3.

Shareholders who have not previously applied to participate in the DIS and who wish to do so in respect of the dividend payable on 26 April 2022, should ensure that a mandate form is received by the Registrar, The City Partnership (UK) Limited, prior to the dividend election date of 8 April 2022.

 

Further to the information disclosed above, the Directors confirm that they are satisfied that all inside information (as defined by Article 7 of the Market Abuse Regulation (596/2014/EU)) that the Directors and the Company may have in their possession relating to the Company during the 30 day closed period leading up to the announcement of its annual results for the year ended 30 November 2021 has been or will be notified to a regulatory information service.

 

Issued on behalf of the Board

Maven Capital Partners UK LLP

Secretary

4 February 2022

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRFIFVAFAISIIF
Date   Source Headline
19th Oct 20234:15 pmRNSNet Asset Value
13th Oct 20234:56 pmRNSPublication of a Prospectus
25th Aug 20239:38 amRNSIssue of Equity
21st Aug 20233:28 pmRNSStatement re Dividend Investment Scheme
21st Jul 202312:52 pmRNSHalf-year Report
13th Jul 20234:04 pmRNSTransaction in Own Shares
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
30th Jun 20234:22 pmRNSNet Asset Value and Interim Dividend
2nd Jun 20239:41 amRNSIssue of Equity
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
26th Apr 202310:15 amRNSIssue of Equity - Dividend Investment Scheme
24th Apr 202312:51 pmRNSResult of AGM
19th Apr 20234:49 pmRNSTransaction in Own Shares
19th Apr 20231:05 pmRNSNet Asset Value - Dividend Investment Scheme
5th Apr 202312:29 pmRNSIssue of Equity
4th Apr 202311:43 amRNSNet Asset Value(s)
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
14th Mar 20234:31 pmRNSAnnual Financial Report
3rd Mar 20239:53 amRNSIssue of Equity
21st Feb 20234:41 pmRNSTransaction in Own Shares
16th Feb 20237:00 amRNSStatement re Offer for Subscription
8th Feb 202311:06 amRNSDirector/PDMR Shareholding - Replacement
8th Feb 202310:19 amRNSDirector/PDMR Shareholding
8th Feb 202310:19 amRNSDirector/PDMR Shareholding
8th Feb 202310:08 amRNSDirector/PDMR Shareholding
8th Feb 20239:43 amRNSIssue of Equity
1st Feb 20233:23 pmRNSUnaudited NAV and Proposed Final Dividend
12th Dec 20223:41 pmRNSDirectorate Change
12th Dec 20223:34 pmRNSStatement re Director's Other Quoted Directorships
9th Nov 20223:00 pmRNSResult of General Meeting
4th Nov 20222:35 pmRNSTransaction in Own Shares
31st Oct 20223:54 pmRNSTransaction in Own Shares
21st Oct 20222:45 pmRNSNet Asset Value(s)
7th Oct 20224:28 pmRNSPublication of a Prospectus
4th Oct 20223:30 pmRNSChange of Auditor
26th Aug 202210:04 amRNSIssue of Equity
22nd Aug 20229:33 amRNSStatement re Dividend Investment Scheme
29th Jul 202211:25 amRNSHalf-year Report
21st Jul 20224:38 pmRNSTransaction in Own Shares
13th Jul 202211:19 amRNSNet Asset Value and Interim Dividend
8th Jul 20223:28 pmRNSStatement re Joint Offers for Subscription
6th Jun 20222:15 pmRNSIssue of Equity
26th May 20225:02 pmRNSTransaction in Own Shares
26th Apr 202212:34 pmRNSIssue of Supplementary Prospectus
26th Apr 202210:51 amRNSIssue of Equity - Dividend Investment Scheme
21st Apr 20222:39 pmRNSStatement re Dividend Investment Scheme
6th Apr 20224:02 pmRNSNet Asset Value(s)
6th Apr 20221:45 pmRNSResult of AGM
5th Apr 20226:30 pmRNSIssue of Equity
23rd Mar 20225:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.